Nephrology Drugs Market by Type (ACE Inhibitor, Calcium Channel Blocker, Diuretics, and Others), Route of Administration (Oral and Parenteral), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online), and Regional Analysis (North America, Europe, Asia-Pacific, and LAMEA): Global Opportunity Analysis and Industry Forecast, 2021-2028

Global Nephrology Drugs Market Analysis

The global nephrology drugs market was valued at $13,723.9 million in 2020 and is projected to reach $21,454.5 million by 2028, registering a CAGR of 6.0%.

Market Synopsis

Increased prevalence of kidney related disorders, especially among geriatric population, is expected to drive the nephrology drugs market size in the forecast time period.

However, high cost of treatment is likely to restrain the nephrology drugs market share growth.

According to the regional analysis of the market, the Asia-Pacific nephrology drugs market is anticipated to grow at a CAGR of 7.0%, by generating a revenue of $4,398.2 million during the review period.

Nephrology Drugs Overview

Nephrology is a branch of medicine that deals with the study of kidney and diseases related to it. Nephrology drugs are often termed as renal medicines and are prescribed by the healthcare professionals to treat various kidney diseases such as kidney infection & stones and improve kidney health. These drugs can either be administered orally or parenteral.

COVID-19 Impact on the Global Nephrology Drugs Market

The occurrence of COVID-19 pandemic has proved to have a negative impact on nephrology drugs market size growth. As the impact of COVID-19 pandemic has had a severe impact on the health and wellbeing of the people across the world, the fear of infection and its severe symptoms has settled in the patients. Amid high rate of corona virus transmission and prevalence of serious symptoms, many patients have deliberately delayed their regular hospital visits and consultations for any other disease. Also, healthcare professionals delayed many renal surgeries and restricted many outpatient visits to contain the deadly virus from transmitting. Apart from this, pharmaceutical industries had put manufacturing of drugs other than corona virus on hold due to which quantity of nephrology drugs became less. Such factors are anticipated to decrease the nephrology drugs market revenue in the coming years.

Increasing Cases of Kidney Diseases to Surge the Market Growth

Rapidly increasing cases of kidney diseases like kidney failure and kidney fibrosis among millennial due to lifestyle changes like less physical exercise and unhealthy food eating habits is expected to drive the nephrology drugs market share growth in the forecast time span. Many people across the world suffer from various kidney diseases such as kidney infection. For instance, according to data collected by National Kidney Foundation in 2018, every year, in the U.S, approximately 37 million people are affected by kidney disease which is equivalent of 15% of the U.S population. Thus, nephrology drugs are the first line of treatment prescribed by the healthcare professionals for managing and preventing spread of any serious kidney related diseases. Also, rising number of geriatric population across the world is further anticipated to raise the growth of nephrology drugs market size in the next few years.

To know more about global nephrology drugs market drivers, get in touch with our analysts here.

High Cost of Nephrology Drugs to Restrain the Market Growth

Nephrology drugs for the treatment of kidney disease are very expensive. Thus, not many patients, especially in the developing nations, can afford such high treatment cost. This factor is likely to hinder the nephrology drugs market share growth of the next few years. Also, not many people are aware about the occurrence of kidney diseases due to which they fail to notice any sign of disease prevalence. Thus, this factor is further expected to impede the market growth in the predicted time period.

Development of Product Portfolio by Major Companies to Fuel the Market Growth

Improvements in the existing nephrology drugs products and new product launches are expected to drive the nephrology drugs market share growth in the future. Major market players in the nephrology drugs market have started focusing on developing and launching new products to meet the rising demand for advanced treatment options for chronic kidney diseases. For instance, according to a news published in Business Standards, an online news portal, on March 07, 2022, Zydus Cadila, a pharmaceutical company, launched a new oral drug named Oxemia (Desidustat) for the treatment of chronic kidney disease. Such factors are anticipated to drive the nephrology drugs market size growth in future.

To know more about global nephrology drugs market opportunities, get in touch with our analysts here.

[TYPEGRAPH]

Source: Research Dive Analysis

The ACE inhibitor nephrology drugs sub-segment is predicted to have the highest revenue in the global market and register a revenue of $8,581.8 million during the forecast period. The growth is attributed to rising prescribed ACE inhibitor drugs by healthcare professionals for the treatment of various diseases. ACE inhibitor drugs are widely used to treat various disorders like chronic kidney disease and heart failure. This factor is likely to surge the sub-segment market growth in the future.

[ROUTEOFADMINISTRATIONGRAPH]

Source: Research Dive Analysis

Oral sub-segment is anticipated to have the fastest market growth rate and generate a revenue of $14,052.7 million in 2028. The increase in the revenue of the sub-segment owes to non-invasive drug administration route of the oral drugs. Intake of oral drugs is very convenient for patients, especially for old age people. Also, rising number of kidney diseases such as kidney failure is anticipated to increase the market growth rate in the predicted time span.

[DISTRIBTIONCHANNELGRAPH]

Source: Research Dive Analysis

The hospital pharmacies sub-segment is predicted to have a dominating market share in the global market and register a revenue of $11,049.0 million during the forecast period. The sub-segment growth is owing to increasing number of patients’ hospital visits with chronic kidney disease. As the number of kidney disease cases has increased, the hospitalization rate has also paced up. Patients find it convenient to purchase the prescribed nephrology drugs from hospital pharmacies as they are in the hospital vicinity. Such factors are anticipated to generate huge market revenues.

Retail pharmacies sub-segment is anticipated to have the fastest market growth and generate a revenue of $9,010.9 million in 2028. Retail pharmacies sub-segment is projected to show an impressive growth owing to the rise in the retail pharmacies outlet across the world. Many people prefer to purchase the medicines from retail pharmacy stores as they are easily available everywhere and the pharmacist also explains the dose intake to the customers. Such factors are likely to flourish the market growth in the forecast time period.

[REGIONGRAPH]

Source: Research Dive Analysis

The Market for Nephrology Drugs in North America to be the Most Dominant

The North America nephrology drugs market accounted $5,558.2 million in 2020 and is projected to register a revenue of $8,581.8 million by 2028. The growth is attributed to the presence of major pharmaceutical companies in the region like Abbott Laboratories. Also, growing geriatric population and the prevalence of chronic kidney diseases like kidney fibrosis in them due to decreased immunity during ageing is further expected to boost the nephrology drugs market size growth in the next few years.

The Market for Nephrology Drugs in Asia-Pacific to Observe the Fastest Growth

The Asia-Pacific nephrology drugs market is expected to observe the fastest growth and register a revenue of $4,398.2 million in the predicted time span. The growth of the region is subjected to rapidly increasing cases of chronic kidney disorders in the middle aged people. Apart from this, major market players have now started investing in launching new products in the region to boost the healthcare facilities in the region. These factors are likely to flourish the nephrology drugs market growth in the next few years.

Competitive Scenario in the Global Nephrology Drugs Market

Product launches and acquisitions are common strategies followed by major market players.

Source: Research Dive Analysis

The companies involved in the nephrology drugs market are AstraZeneca, AbbVie Inc., Akebia Therapeutics, Inc., Amgen Inc., F. Hoffmann-La Roche, FibroGen Inc., GlaxoSmithkline PLC., Johnson & Johnson Inc., Pfizer Inc., and Teva Pharmaceutical Industries Limited.

Porter’s Five Forces Analysis for the Global Nephrology Drugs Market

• Bargaining Power of Suppliers: The suppliers in the nephrology drugs market are high in number. Several companies are working on drug development. Due to this, suppliers have to optimize their product price range to attract their customers.
  Thus, the bargaining power suppliers is moderate.
• Bargaining Power of Buyers: Buyers are growing in number and have huge bargaining power, they demand best and advanced products at low prices. But the price designated for the medicines are nearly standardized. Thus, the patients have restricted option to purchase medicines. 
  Thus, the bargaining power of the buyers is moderate.
• Threat of New Entrants: New companies entering the nephrology drugs market are launching new nephrology drugs in the market in minimum time frame. 
  Thus, the threat of the new entrants is high.
• Threat of Substitutes: Since nephrology drugs are used to control kidney disease, no suitable substitute is available in the market.
  Thus, the threat of substitutes is low.
• Competitive Rivalry in the Market: The competitive rivalry among industry leaders is rather intense, especially between the global players. These companies are launching their new products in the international market and strengthening the footprint worldwide. 
  Therefore, competitive rivalry in the market is high.

1.Research Methodology

1.1.Desk Research
1.2.Real time insights and validation
1.3.Forecast model
1.4.Assumptions and forecast parameters

1.4.1.Assumptions
1.4.2.Forecast parameters

1.5.Data sources

1.5.1.Primary
1.5.2.Secondary

2.Executive Summary

2.1.360° summary
2.2.Type trends
2.3.Route of Administration trends
2.4.Distribution channel trends

3.Market overview

3.1.Market segmentation & definitions
3.2.Key takeaways

3.2.1.Top investment pockets
3.2.2.Top winning strategies

3.3.Porter’s five forces analysis

3.3.1.Bargaining power of consumers
3.3.2.Bargaining power of suppliers
3.3.3.Threat of new entrants
3.3.4.Threat of substitutes
3.3.5.Competitive rivalry in the market

3.4.Market dynamics

3.4.1.Drivers
3.4.2.Restraints
3.4.3.Opportunities

3.5.Technology landscape
3.6.Regulatory landscape
3.7.Patent landscape
3.8.Market value chain analysis
3.9.Strategic overview

4.Nephrology Drugs Market, by Type 

4.1.ACE Inhibitor

4.1.1.Key market trends, growth factors, and opportunities
4.1.2.Market size and forecast, by region, 2020-2028
4.1.3.Market share analysis, by country, 2020 & 2028

4.2.Calcium Channel Blocker

4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region, 2020-2028
4.2.3.Market share analysis, by country, 2020 & 2028

4.3.Diuretics

4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region, 2020-2028
4.3.3.Market share analysis, by country, 2020 & 2028

4.4.Others 

4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by region, 2020-2028
4.4.3.Market share analysis, by country, 2020 & 2028

5.Nephrology Drugs Market, by Route of Administration 

5.1.Oral 

5.1.1.Key market trends, growth factors, and opportunities
5.1.2.Market size and forecast, by region, 2020-2028
5.1.3.Market share analysis, by country, 2020 & 2028

5.2.Parenteral 

5.2.1.Key market trends, growth factors, and opportunities
5.2.2.Market size and forecast, by region, 2020-2028
5.2.3.Market share analysis, by country, 2020 & 2028

6.Nephrology Drugs Market, by Distribution Channel 

6.1.Hospital Pharmacies 

6.1.1.Key market trends, growth factors, and opportunities
6.1.2.Market size and forecast, by region, 2020-2028
6.1.3.Market share analysis, by country, 2020 & 2028

6.2.Retail Pharmacies 

6.2.1.Key market trends, growth factors, and opportunities
6.2.2.Market size and forecast, by region, 2020-2028
6.2.3.Market share analysis, by country, 2020 & 2028

6.3.Online

6.3.1.Key market trends, growth factors, and opportunities
6.3.2.Market size and forecast, by region, 2020-2028
6.3.3.Market share analysis, by country, 2020 & 2028

7.Nephrology Drugs Market, by Region

7.1.North America

7.1.1.Key market trends, growth factors, and opportunities
7.1.2.Market size and forecast, by Type, 2020-2028
7.1.3.Market size and forecast, by Route of Administration, 2020-2028
7.1.4.Market size and forecast, by Distribution Channel, 2020-2028
7.1.5.Market size and forecast, by country, 2020-2028

7.1.6.U.S.

7.1.6.1.Market size and forecast, by Type, 2020-2028
7.1.6.2.Market size and forecast, by Route of Administration, 2020-2028
7.1.6.3.Market size and forecast, by Distribution Channel, 2020-2028

7.1.7.Canada

7.1.7.1.Market size and forecast, by Type, 2020-2028
7.1.7.2.Market size and forecast, by Route of Administration, 2020-2028
7.1.7.3.Market size and forecast, by Distribution Channel, 2020-2028

7.1.8.Mexico

7.1.8.1.Market size and forecast, by Type, 2020-2028
7.1.8.2.Market size and forecast, by Route of Administration, 2020-2028
7.1.8.3.Market size and forecast, by Distribution Channel, 2020-2028

7.2.Europe

7.2.1.Key market trends, growth factors, and opportunities
7.2.2.Market size and forecast, by Type, 2020-2028
7.2.3.Market size and forecast, by Route of Administration, 2020-2028
7.2.4.Market size and forecast, by Distribution Channel, 2020-2028
7.2.5.Market size and forecast, by country, 2020-2028

7.2.6.Germany 

7.2.6.1.Market size and forecast, by Type, 2020-2028
7.2.6.2.Market size and forecast, by Route of Administration, 2020-2028
7.2.6.3.Market size and forecast, by Distribution Channel, 2020-2028
7.2.6.4.Comparative market share analysis, 2020 & 2028

7.2.7.UK

7.2.7.1.Market size and forecast, by Type, 2020-2028
7.2.7.2.Market size and forecast, by Route of Administration, 2020-2028
7.2.7.3.Market size and forecast, by Distribution Channel, 2020-2028

7.2.8.France

7.2.8.1.Market size and forecast, by Type, 2020-2028
7.2.8.2.Market size and forecast, by Route of Administration, 2020-2028
7.2.8.3.Market size and forecast, by Distribution Channel, 2020-2028

7.2.9.Spain

7.2.9.1.Market size and forecast, by Type, 2020-2028
7.2.9.2.Market size and forecast, by Route of Administration, 2020-2028
7.2.9.3.Market size and forecast, by Distribution Channel, 2020-2028

7.2.10.Italy

7.2.10.1.Market size and forecast, by Type, 2020-2028
7.2.10.2.Market size and forecast, by Route of Administration, 2020-2028
7.2.10.3.Market size and forecast, by Distribution Channel, 2020-2028

7.2.11.Rest of Europe

7.2.11.1.Market size and forecast, by Type, 2020-2028
7.2.11.2.Market size and forecast, by Route of Administration, 2020-2028
7.2.11.3.Market size and forecast, by Distribution Channel, 2020-2028

7.3.Asia Pacific

7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Market size and forecast, by Type, 2020-2028
7.3.3.Market size and forecast, by Route of Administration, 2020-2028
7.3.4.Market size and forecast, by Distribution Channel, 2020-2028
7.3.5.Market size and forecast, by country, 2020-2028

7.3.6.China

7.3.6.1.Market size and forecast, by Type, 2020-2028
7.3.6.2.Market size and forecast, by Route of Administration, 2020-2028
7.3.6.3.Market size and forecast, by Distribution Channel, 2020-2028

7.3.7.Japan 

7.3.7.1.Market size and forecast, by Type, 2020-2028
7.3.7.2.Market size and forecast, by Route of Administration, 2020-2028
7.3.7.3.Market size and forecast, by Distribution Channel, 2020-2028

7.3.8.India

7.3.8.1.Market size and forecast, by Type, 2020-2028
7.3.8.2.Market size and forecast, by Route of Administration, 2020-2028
7.3.8.3.Market size and forecast, by Distribution Channel, 2020-2028

7.3.9.South Korea

7.3.9.1.Market size and forecast, by Type, 2020-2028
7.3.9.2.Market size and forecast, by Route of Administration, 2020-2028
7.3.9.3.Market size and forecast, by Distribution Channel, 2020-2028

7.3.10.Australia

7.3.10.1.Market size and forecast, by Type, 2020-2028
7.3.10.2.Market size and forecast, by Route of Administration, 2020-2028
7.3.10.3.Market size and forecast, by Distribution Channel, 2020-2028

7.3.11.Rest of Asia Pacific

7.3.11.1.Market size and forecast, by Type, 2020-2028
7.3.11.2.Market size and forecast, by Route of Administration, 2020-2028
7.3.11.3.Market size and forecast, by Distribution Channel, 2020-2028

7.4.LAMEA

7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Market size and forecast, by Type, 2020-2028
7.4.3.Market size and forecast, by Route of Administration, 2020-2028
7.4.4.Market size and forecast, by Distribution Channel, 2020-2028
7.4.5.Market size and forecast, by country, 2020-2028

7.4.6.Latin America  

7.4.6.1.Market size and forecast, by Type, 2020-2028
7.4.6.2.Market size and forecast, by Route of Administration, 2020-2028
7.4.6.3.Market size and forecast, by Distribution Channel, 2020-2028

7.4.7.Middle East 

7.4.7.1.Market size and forecast, by Type, 2020-2028
7.4.7.2.Market size and forecast, by Route of Administration, 2020-2028
7.4.7.3.Market size and forecast, by Distribution Channel, 2020-2028

7.4.8.Africa

7.4.8.1.Market size and forecast, by Type, 2020-2028
7.4.8.2.Market size and forecast, by Route of Administration, 2020-2028
7.4.8.3.Market size and forecast, by Distribution Channel, 2020-2028

8.Company profiles

8.1.AstraZeneca

8.1.1.Company overview
8.1.2.Operating business segments
8.1.3.Product portfolio
8.1.4.Financial performance
8.1.5.Key strategy moves and development

8.2.AbbVie Inc.

8.2.1.Company overview
8.2.2.Operating business segments
8.2.3.Product portfolio
8.2.4.Financial performance
8.2.5.Key strategy moves and development

8.3.Akebia Therapeutics

8.3.1.Company overview
8.3.2.Operating business segments
8.3.3.Product portfolio
8.3.4.Financial performance
8.3.5.Key strategy moves and development

8.4.Amgen Inc.

8.4.1.Company overview
8.4.2.Operating business segments
8.4.3.Product portfolio
8.4.4.Financial performance
8.4.5.Key strategy moves and development

8.5.F. Hoffmann-La Roche

8.5.1.Company overview
8.5.2.Operating business segments
8.5.3.Product portfolio
8.5.4.Financial performance
8.5.5.Key strategy moves and development

8.6.FibroGen Inc

8.6.1.Company overview
8.6.2.Operating business segments
8.6.3.Product portfolio
8.6.4.Financial performance
8.6.5.Key strategy moves and development

8.7.GlaxoSmithkline PLC.

8.7.1.Company overview
8.7.2.Operating business segments
8.7.3.Product portfolio
8.7.4.Financial performance
8.7.5.Key strategy moves and development

8.8.Johnson & Johnson Inc.

8.8.1.Company overview
8.8.2.Operating business segments
8.8.3.Product portfolio
8.8.4.Financial performance
8.8.5.Key strategy moves and development

8.9.Teva Pharmaceutical Industries Limited

8.9.1.Company overview
8.9.2.Operating business segments
8.9.3.Product portfolio
8.9.4.Financial performance
8.9.5.Key strategy moves and development

8.10.Pfizer Inc.

8.10.1.Company overview
8.10.2.Operating business segments
8.10.3.Product portfolio
8.10.4.Financial performance
8.10.5.Key strategy moves and development

* Taxes/Fees, If applicable will be added during checkout. All prices in USD.